Results 71 to 80 of about 33,833 (238)

Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments

APMIS, Volume 134, Issue 3, March 2026.
ABSTRACT Biofilms formed by mycobacteria, particularly Mycobacterium tuberculosis (Mtb), represent a major challenge in tuberculosis (TB) treatment due to their highly organized structure and their capacity to induce phenotypic drug tolerance. These three‐dimensional bacterial aggregates are embedded in a self‐produced extracellular matrix that ...
Lourdes Serrano Garcia, Cesar Augusto Roque‐Borda, Fernando Rogério Pavan, Marlus Chorilli   +3 more
wiley   +1 more source

High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia

Emerging Infectious Diseases
Bedaquiline is a cornerstone drug for treating drug-resistant tuberculosis. We analyzed 11 isolates from 9 patients who were treated with a bedaquiline-based regimen and remained culture-positive long after treatment start. In 4 of 8 resistant isolates,
Danila Zimenkov, Anastasia Ushtanit, Elizaveta Gordeeva, Elena Guselnikova, Yakov Schwartz, Natalia Stavitskaya   +5 more
doaj   +1 more source

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The new antituberculous drugs delamanid and bedaquiline form the last line of defence against drug-resistant tuberculosis (TB). Understanding the background prevalence of resistance to new drugs can help predict the lifetime of these drugs’
Wencong He, Chunfa Liu, Dongxin Liu, Aijing Ma, Yimeng Song, Ping He, Jingjing Bao, Yuanchun Li, Bing Zhao, Jiale Fan, Qian Cheng, Yanlin Zhao   +11 more
doaj   +1 more source

Cytotoxicity and Antimicrobial Activity of GaMF1 Analogs

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
GaMF1 is a reported, highly potent inhibitor of mycobacterial ATP synthase. Structural modification of this scaffold significantly changes biological activity. We present GaMF1 analogues with strong antiparasitic effects, potential antiproliferative properties, and discuss the selectivity limitations of the parent compound and its analogues.
Jan Chasák, Petr Vyvlečka, Ivan Nemec, An Matheeussen, Natascha Van Pelt, Paul Cos, Guy Caljon, Vladimír Kryštof, Lucie Brulíková   +8 more
wiley   +1 more source

Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis

Frontiers in Medicine
Clofazimine (CFZ) and bedaquiline (BDQ) are currently used for the treatment of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains.
Md Mahmudul Islam, Md Shah Alam, Zhi-yong Liu, Mst Sumaia Khatun, Buhari Yusuf, H. A. Hameed, Xirong Tian, C. Chhotaray, Rajesh Basnet, H. Abraha, Xiaofan Zhang, Shahzad Akbar Khan, Cuiting Fang, Chunyu Li, Sohel Hasan, Shouyong Tan, Nanshan Zhong, Jinxing Hu, Tianyu Zhang   +18 more
semanticscholar   +1 more source

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis

Clinical Infectious Diseases, 2022
Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low globally. Availability of newer drugs has given scope to develop regimens that can be patient-friendly, less toxic, with improved outcomes.
C. Padmapriyadarsini, V. Vohra, Anuj Bhatnagar, Rajesh Solanki, R. Sridhar, L. Anande, M. Muthuvijaylakshmi, Meera Bhatia Rana, B. Jeyadeepa, Gaurav Taneja, S. Balaji, Prashant L Shah, N. Saravanan, Vijay Chavan, Hemanth Kumar, C. Ponnuraja, V. Livchits, Monica Bahl, U. Alavadi, K. Sachdeva, S. Swaminathan, C B Nabila Edwin S S M C Hemanth N R R Vikram Meera Padmapriyadarsini Jeyadeepa Lakshana Akbar Arulraj, C. Padmapriyadarsini, B. Jeyadeepa, Lakshana, N. Akbar, Edwin Arulraj, Karthikeyan., Muthukumar, Tamizharasan, S. Shivakumar, M. Muthuvijayalakshmi, Gayathri, C. Ponnuraja, R. Sridhar, R. Kumar, Ramesh, V. Vohra, Meera Bhatia Rana, N. Singla, V. Myneedu, A. Lawrence, Dipti Kushwaha, Deepak Kheraliya Shivam, R. Sarin, Anuj Bhatnagar, Gaurav Taneja, Alok Rawat, M. Haniff, Rahul, Padma Rai, Savita Saini, Krisha Mathur, Rajesh Solanki, P. Patel, V.M. Prajapati, Bhavesh Parmar, Kajal Wadkar, Prashant L Shah, Snehal Parmar, Palak Vyas, Krupa Mistri, Lalitkumar Anade, Vijay Chavan, N. K. Bhui, P. Tipre, D. Shah, Surendra K Patwa, Anis Nhavakar, A. Brito, K. Keny, Vijaykumar Karanjkar, Kuntal Pal, Komal Godam, Madri Huje, S. Ghadge, Madhuri Udmalle, Vivek Vijay Posture, Jaipal Bansode, Monica Bhal, Ranjan, Divya Pillai, Supriya Semwal, Shirali Labroo Viktoriya Livchits, U. Alavadi, Reuben Swamikan, Dorothy Nanzala Nasubo, Mallik Parmar, S. Sahu, Y. Mukadi, S. Swaminathan   +90 more
semanticscholar   +1 more source

Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis [PDF]

, 2015
Pharmacokinetic drug-drug interactions (DDIs) can lead to undesired drug exposure, resulting in insufficient efficacy or aggravated toxicity. Accurate quantification of DDIs is therefore crucial but may be difficult when full concentration-time profiles ...
Björn Clauson, Chayan Acharya, Elin M. Svensson, Kelly E. Dooley, Mats O. Karlsson   +4 more
core   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Scientific Reports
The treatment of multidrug-resistant tracheobronchial tuberculosis poses challenges, and research investigating the efficacy of bedaquiline or delamanid as treatment for this condition is limited.
Qing Chen, Tao Huang, Liping Zou, Xianzhen Tang, Zhengyu Shi, Xinwei Wang, Huaige Wu, Jiying Sun, Xiaoli Lu, Li Liang, Liangshuang Jiang, Dafeng Liu, Shenjie Tang, Guihui Wu, Wei He   +14 more
doaj   +1 more source

Effectiveness and Safety of the Regimens Containing Bedaquiline in Patients with TB and HIV-infection

Туберкулез и болезни лёгких
The objective: to analyze effectiveness and safety of bedaquiline administered concurrently with antiretroviral therapy in treatment regimens for patients with such comorbidities as HIV infection and multiple drug resistant and extensively drug resistant
S. B. Borisova, N. Yu. Borodina
doaj   +1 more source